FIELD: medicine.
SUBSTANCE: invention refers to biochemistry, particularly to artificial immunogenic proteins having the properties of melanoma antigens. What is declared is an artificial gene coding MEL-TCI-A0201 polyepitope immunogenic protein containing multiple cytotoxic restricted HLA-A*0201 and T-helper epitopes of NY-ESO-1, MART1, MAGE-A1, MAGE-A3, MAGE-A11, MAGE-C1 melanoma antigens, having a sequence of 1,535 base pairs presented in Fig. 3. There are also declared a recombinant plasmid DNA containing the above artificial gene, and MEL-TCI-A0201 immunogenic protein with the properties of the melanoma antigens.
EFFECT: invention enables providing higher immunogenicity of the artificial polyepitope T-cell immunogen inducing a higher level of cytotoxic T-lymphocyte response.
3 cl, 11 dwg, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ARTIFICIAL GENE MEL-TCI, CODING POLYEPITOPIC PROTEIN-IMMUNOGENE MEL-TCI, RECOMBINANT PLASMID DNA PMEL-TCI PROVIDING EXPRESSION OF ARTIFICIAL GENE MEL-TCI AND ARTIFICIAL PROTEIN-IMMUNOGENE MEL-TCI, CONTAINING CTL- AND Th-DETERMINANTS OF MELANOMA ANTIGENES RESTRUCTURED BY PLURAL ALLELS HLA OF I AND II CLASS | 2017 |
|
RU2650872C1 |
| ARTIFICIAL PROTEIN-IMMUNOGEN TCI COMPRISING MULTIPLE CTL-EPITOPES OF HIV-1 BASIC ANTIGENS, ARTIFICIAL GENE TCI ENCODING POLYEPITOPE PROTEIN-IMMUNOGEN TCI | 2002 |
|
RU2238946C2 |
| RECOMBINANT PLASMID DNA PCDNA-TCI PROVIDING EXPRESSION OF ARTIFICIAL GENE TCI IN EUCARYOTIC CELLS AND RECOMBINANT ATTENUATED STRAIN OF BACTERIUM SALMONELLA ENTERITIDIS E-23 PC-DNA-TCI AS CANDIDATE FOR CONSTRUCTION OF LIVE DNA-VACCINE AGAINST HUMAN IMMUNODEFICIENCY VIRUS | 2003 |
|
RU2248396C2 |
| ARTIFICIAL GENE ENCODING THE BSI-COV IMMUNOGEN PROTEIN, PBSI-COV RECOMBINANT PLASMID DNA PROVIDING EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL BSI-COV POLYEPITOPE IMMUNOGEN PROTEIN CONTAINING EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2- SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806556C1 |
| ARTIFICIAL GENE ENCODING THE BSI-COV-UB IMMUNOGEN PROTEIN, RECOMBINANT PLASMID DNA PBSI-COV-UB, WHICH ENSURES THE EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL POLYEPITOPE BSI-COV-UB IMMUNOGEN PROTEIN CONTAINING UBIQUITIN AND EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2-SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806590C1 |
| ARTIFICIAL GENES CODING EV.CTL AND EV.Th PROTEINS-IMMUNOGENS, RECOMBINANT PLASMID DNA pEV.CTL AND EV.Th, PROVIDING EXPRESSION OF ARTIFICIAL GENES, AND ARTIFICIAL T-CELL POLYEPITOPE PROTEINS-IMMUNOGENS EV.CTL AND EV.Th CONTAINING EPITOPES OF EBOLA VIRUS ANTIGENS, USED TO CREATE AN EBOLA VIRUS VACCINE | 2018 |
|
RU2713723C1 |
| POLYEPITOPE IMMUNOGENIC POLYPEPTIDES AND METHODS OF APPLICATION THEREOF | 2013 |
|
RU2598265C2 |
| RECOMBINANT ONCOLYTIC STRAIN OF L-IVP_ONCOM VACCINIA VIRUS, CONTAINING GENES, ENCODING GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR AND POLYEPITOPE IMMUNOGEN CONSISTING OF ANTIGEN EPITOPES, OVEREXPRESSING TUMOR CELLS IN MELANOMA | 2017 |
|
RU2678060C1 |
| POLYEPITOPE ANTI-TUMOUR VACCINE STRUCTURE CONTAINING EPITOPES OF TUMOR-ASSOCIATED ANTIGENS, PHARMACEUTICAL COMPOSITION AND ITS APPLICATION FOR STIMULATING SPECIFIC ANTI-TUMOR IMMUNE RESPONSE | 2016 |
|
RU2684235C2 |
| RECOMBINANT VACCINE AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 | 2006 |
|
RU2317107C2 |
